AstraZeneca's Covid Antibody Therapy to Be Manufactured by Samsung Biologics

Samsung Biologics is the biotech arm of Samsung Group that will aid in manufacturing AstraZeneca’s antibody combination against COVID-19.

Under an agreement valued at approximately $380 million, Samsung Biologics will manufacture Evusheld – AstraZeneca’s combination of two long-acting antibodies in development for the potential treatment of COVID-19 – at its plant in Songdo, Incheon, 40 km west of Seoul, Yonhap news agency reported.

Covid Antibody Drug Effective Against Omicron
Sotrovimab, a monoclonal antibody, is effective for people who do not require oxygen supplementation. It also helps in reducing the risk of hospitalization.

‘Evusheld is the first antibody treatment that was approved for Emergency Use Authorization by the US Food and Drug Administration (FDA).’

Tweet it Now

The deal represents a hike from a long-term supply agreement valued at $331 million signed between the two firms in September.

Evusheld is an injectable monoclonal antibody cocktail and has been approved for pre-exposure prophylaxis, or PrEP, against COVID-19 among individuals aged 12 and older and who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2.

It is the first antibody treatment against COVID-19 that has won an Emergency Use Authorization from the US Food and Drug Administration (FDA). It has also won approval from drug authorities in other countries, including France and Italy.

Cipla Launches COVID Antibody Cocktail in India
Antibody cocktail contains casirivimab and Imdevimab, to be administered for the treatment of mild to moderate COVID-19 in adults and kids.

The cocktail is made up of Tixagevimab and cilgavimab — long-acting monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2. It is designed to block the virus’ attachment and entry into human cells. Tixagevimab and cilgavimab bind to different, non-overlapping sites on the spike protein of the virus, the FDA said.

AstraZeneca has also said it is testing Evusheld against the new Omicron variant, that has so far spread to more than 60 countries.

Mepolizumab Antibody Therapy to Help Treatment of Resistant COPD Patients
About 40% of COPD patients are resistant to standard treatment and continue to have flare ups; mepolizumab, an antibody therapy may help them, says study.

The deal also includes Samsung Bioglogics manufacturing AstraZeneca’s oncology drug Imfinzi at its plant starting next year, the report said.

Imfinzi has won approval in many countries, including South Korea, for the treatment of lung cancer. The drug is currently under study for the treatment of other cancers.

Antibody Identified That Is Effective Against Both Dengue And Zika Virus Infection
Anti-dengue virus antibody identified, that is effective and protects from both dengue as well as Zika virus infections.

Source-IANS